Skip to main content
. 2020 Jun 30;1(8):824–828. doi: 10.34067/KID.0002692020

Table 1.

Biopsy characteristics including date, indication, brief clinical history, and final diagnosis

Case Biopsy Type Biopsy Date Biopsy Indication Clinical History Biopsy Diagnosis
1 N April 2020 Proteinuria (10 g), increased Cr (1.7) 33 yr F with DM2, CHF Diffuse and nodular glomerulosclerosis, consistent with diabetic nephropathy, class 3
2 N April 2020 AKI (Cr 2.7), low C4 75 yr M with HTN, hyperlipidemia, CVA, lung cavitary lesions Mesangiopathic immune complex disease, most consistent with resolving-phase infectious glomerulonephritis
3 N April 2020 AKI (Cr 8.4) 46 yr M with hematuria, hemoptysis, and weakness Diffuse crescentic and necrotizing GN, pauci-immune (ANCA-associated) type
4 N April 2020 AKI (Cr 1.5) 33 yr M with h/o methamphetamine abuse Thrombotic microangiopathy
5 N March 2020 Rapid decline of renal function 72 yr M with DM2, HTN on hydralazine. Positive ANA (1:640) and ANCA Mesangiopathic immune complex disease, suspicious for autoimmune diseases such as lupus or lupus-like conditions
6 N March 2020 History of IgAN, now nephrotic-range proteinuria 40 yr, Cr 1.3;UA: 3+ blood, 3+ protein IgAN with focal cellular crescents and fibrinoid necrosis
7 T March 2020 AKI (Cr 7.9) 47 yr M with ESKD from DM/HTN Acute cellular rejection, Banff IB
Acute vascular rejection, Banff IIB
C4d negative
SV-40 negative
8 T March 2020 AKI (Cr 2.7) 55 yr M with ESKD from RCC requiring bilateral nephrectomies Borderline changes by Banff criteria (suspicious for acute cellular rejection)
C4d negative
SV-40 negative
9 T March 2020 AKI (Cr 4.3), anemia, leukopenia 28 yr M with ESKD of unknown etiology Acute cellular rejection, Banff IB
Acute vascular rejection, Banff IIB
C4d negative
SV-40 negative
10 T February 2020 AKI (Cr 5.1) 36 yr F with h/o ESKD due to SLE. Admitted with pulmonary HTN, acute decompensated HFpEF, and AKI. DSAs negative Negative for rejection
Findings favor thrombotic microangiopathy
C4d negative
SV-40 negative
11 T October 2019 AKI (Cr 6.5) 49 yr M with ESKD from DM/HTN s/p DDKT with DGF Negative for rejection
C4d negative
SV-40 negative
12 T October 2019 AKI (Cr 1.7) 53 yr with ESKD from DM2 Borderline changes by Banff criteria
C4d negative
SV-40 negative
13 T October 2019 AKI (Cr 4.6) 38 yr M with HTN, AFib, HLPD, s/p kidney transplant with diarrhea Acute cellular rejection, Banff IA
C4d positive
SV-40 negative
14 T October 2019 Pain over allograft, AKI (Cr 1.8) 40 yr M with ESKD from HTN/DM BK polyomavirus nephropathy
Negative for rejection
C4d negative
SV-40 positive
15 T October 2019 AKI (Cr 2.7) 67 yr F with ESKD from DM/HTN Borderline changes by Banff criteria
C4d negative
SV-40 negative

N, native kidney; Cr, creatinine (all values are in mg/dl; reference range, 0.6–1.3 mg/dl); F, female; DM2, type 2 diabetes mellitus; CHF, congestive heart failure; M, male; HTN, hypertension; CVA, cerebrovascular accident; h/o, history of; ANA, anti-nuclear antibodies; IgAN, IgA nephropathy; UA, urinalysis; T, transplant kidney; SV-40, simian virus 40; RCC, renal cell carcinoma; HFpEF, heart failure with preserved ejection fraction; DSA, donor-specific antibody; s/p, status post; DDKT, deceased donor kidney transplant; DGF, delayed graft function; AFib, atrial fibrillation; HLPD, hyperlipidemia.

HHS Vulnerability Disclosure